India to Kenya: Vaccine Export Trade Route

The India to Kenya Vaccine corridor is one of India's established pharmaceutical export routes, with 772 shipments documented worth a combined $55.9M USD. The route is dominated by BHARAT BIOTECH INTERNATIONAL LIMITED, which alone accounts for roughly 71% of all export value, reflecting the consolidated nature of India's vaccine manufacturing sector.

Across 37 active suppliers, the average shipment value stands at $72.5K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 85% of all shipments, consistent with vaccine's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 30 days port-to-port. The route has recorded an annual growth rate of 34.1%, placing it at rank #11 among India's top vaccine export destinations globally.

On the import side, key buyers of Indian vaccine in Kenya include NATIONAL VACCINES AND IMMUNIZATION, NATIONAL VACCINE AND IMMUNIZATION , UNICEF KENYA COUNTRY OFFICE P O BOX and 76 others. NATIONAL VACCINES AND IMMUNIZATION is the single largest importer with 34 shipments valued at $38.5M USD.

India's vaccine exports to Kenya are driven primarily by a handful of large-scale manufacturers. BHARAT BIOTECH INTERNATIONAL LIMITED with 47 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 37 active exporters signals a competitive but concentrated market — buyers in Kenya benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — BHARAT BIOTECH INTERNATIONAL LIMITED, SERUM INSTITUTE OF INDIA PRIVATE LIMITED, BIOLOGICAL E LIMITED — together account for 82% of total trade value on this route. The average shipment value of $72.5K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as typbar tcv-2.5 ml(5 dose) vial (typhoidvi conjugate vaccine) and s359348 mr vaccine measles and rubella, suggesting that buyers in Kenya tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, NATIONAL VACCINES AND IMMUNIZATION is the largest importer with 34 shipments worth $38.5M USD — representing 69% of all vaccine imports from India on this route. A total of 79 buyers are active on this corridor.